Lokaltherapie chronischer Wunden bei Patienten mit den ... - AWMF

S3-Leitlinie 091-001 „Lokaltherapie chronischer Wunden bei den Risiken CVI, PAVK und Diabetes mellitus“
206. Falabella AF, Carson P, Eaglstein WH, Falanga V. The safety and efficacy of a proteolytic
ointment in the treatment of chronic ulcers of the lower extremity. Journal of the American Academy
of Dermatology. 1998;39(5 Pt 1):737-40.
207. Palmieri B, Magri M. A new formulation of collagenase ointment (Iruxol mono) in the
treatment of ulcers of the lower extremities. A randomised, placebo-controlled, double-blind study.
Clinical Drug Investigation. 1998;15(5):381-7.
208. Ramundo J, Gray M. Enzymatic wound debridement. JWound Ostomy ContinenceNurs.
2008;35(3):273-80.
209. Vasel - Biergans A, Probst W. Wundauflagen. Stuttgart: Wissenschaftliche Verlagsgesellschaft
2010.
210. Iruxol N. Gebrauchsinformation. Stand der Information Mai 2005.2005 01.12.2011. Available
from: http://www.parcelmed.de/pdf/1567708.pdf.
211. Jull AB, Rogers A, Walker N. Honey as a topical treatment for wounds. Cochrane Database of
Systematic Reviews: Reviews. 2008;Issue 4.
212. APOFit Arzneimittelvertrieb GmbH. Produktinformation Medihoney2010.
213. Molan PC, Betts JA. Clinical usage of honey as a wound dressing: an update. J WoundCare.
2004;13(9):353-6.
214. Molan PC. The antibacterial activity of honey: 1. The nature of the antibacterial activity. Bee
World. 1992;73(1):5-28.
215. d'Agostino B, La Rosa C, Zanelli C. Attivit antibatterica di mieli Siciliani [Antibacterial activity
of Sicilian honeys]. Quad Nutr. 1961;21(1/2):30-44.
216. Cooper RA, Molan PC, Harding KG. Antibacterial activity of honey against strains of
Staphylococcus aureus from infected wounds. J RSocMed. 1999;92(6):283-5.
217. Molan PC. The evidence supporting the use of honey as a wound dressing. IntJ Low
ExtremWounds. 2006;5(1):40-54.
218. Gethin GT, Cowman S, Conroy RM. The impact of Manuka honey dressings on the surface pH
of chronic wounds. International Wound Journal. 2008;5(2):185-94.
219. Vandeputte J, Gryson L. Diabetic foot infection controlled by immuno-modulating hydrogel
containing 65% glycerine. Presentation of a clinical trial. 6th European Conference on Advances in
Wound Management, AmsterdamOctober 1996. London: MacmillanMagazines. 1997:3-50.
220. Kramer A, Adrian V, Rudolph P, Wurster S. Explanationstest mit Haut und Peritoneum der
neonatalen Ratte als Voraussagetest zur Verträglichkeit lokaler Antiseptika für Wunden und
Körperhöhlen. Chirurg. 1998;69(8):840-5.
221. Faria G, Cardoso CR, Larson RE, Silva JS, Rossi MA. Chlorhexidine-induced apoptosis or
necrosis in L929 fibroblasts: A role for endoplasmic reticulum stress. ToxicolApplPharmacol.
2009;234(2):256-65.
222. Kalteis T, Luring C, Schaumburger J, Perlick L, Bathis H, Grifka J. [Tissue toxicity of antiseptics].
ZOrthopIhre Grenzgeb. 2003;141(2):233-8.
223. Lee TH, Hu CC, Lee SS, Chou MY, Chang YC. Cytotoxicity of chlorhexidine on human
osteoblastic cells is related to intracellular glutathione levels. IntEndodJ. 2010;43(5):430-5.
224. Globopharm AG. Fachinformationen Hibidil© Sterile Lösung. Globopharm AG, 8700 K snacht
ZH. 2004.
225. Barbaud A, Collet E, Le Coz CJ, Meaume S, Gillois P. Contact allergy in chronic leg ulcers:
results of a multicentre study carried out in 423 patients and proposal for an updated series of patch
tests. Contact Dermatitis. 2009;60(5):279-87. Epub 2009/04/29.
226. Machet L, Couhe C, Perrinaud A, Hoarau C, Lorette G, Vaillant L. A high prevalence of
sensitization still persists in leg ulcer patients: a retrospective series of 106 patients tested between
2001 and 2002 and a meta-analysis of 1975-2003 data. [29 refs]. British Journal of Dermatology.
2004;150(5):929-35.
227. Gallenkemper G, Fau - Rabe E, Bauer R. Contact sensitization in chronic venous insufficiency:
modern wound dressings. (0105-1873 (Print)).
Seite 264 von 279 aktueller Stand: 12.06.2012